Cecilia Jones sold $81k of AGIO
Chief Financial Officer at AGIOS PHARMACEUTICALS, INC.. 2,275 shares at an average of $35.54, traded Mar 3, 2025, filed Mar 4, 2025.
Score components
- +22RoleCFO
- +9Trade size$81k at market
- +5Share of holdings soldSold 10% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001439222-25-000019, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2025 | MOption exercise Common stock10b5-1 | +2,000 | $0.00 | $0 | 22,437 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common stock10b5-1 | -594 | $35.54 | $21k | 21,843 | Mar 4, 2025 |
| Mar 1, 2025 | MOption exercise Common stock10b5-1 | +5,667 | $0.00 | $0 | 27,510 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common stock10b5-1 | -1,681 | $35.54 | $60k | 25,829 | Mar 4, 2025 |
| Mar 1, 2025 | AGrant or award Restricted stock unitsderivative10b5-1 | +12,000 | $0.00 | $0 | 12,000 | Mar 4, 2025 |
| Mar 1, 2025 | AGrant or award Restricted stock unitsderivative10b5-1 | +15,910 | $0.00 | $0 | 15,910 | Mar 4, 2025 |
| Mar 1, 2025 | AGrant or award Stock options (right to buy)derivative10b5-1 | +43,500 | $0.00 | $0 | 43,500 | Mar 4, 2025 |
| Mar 1, 2025 | MOption exercise Restricted stock unitsderivative10b5-1 | -2,000 | $0.00 | $0 | 2,000 | Mar 4, 2025 |
| Mar 1, 2025 | MOption exercise Restricted stock unitsderivative10b5-1 | -5,667 | $0.00 | $0 | 11,333 | Mar 4, 2025 |
Related signals
Other insiders at AGIOS PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | AGIOS PHARMACEUTICALS, INC. | David Scadden director | $8,768 200 shares | -1% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $107k 2,454 shares | -4% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $8,762 200 shares | -0% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | Sarah Gheuens Chief Medical Officer | $145k 3,302 shares | -5% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | David Scadden director | $8,200 200 shares | -1% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | David Scadden director | $8,000 200 shares | -1% | |
| 6Weak | AGIOS PHARMACEUTICALS, INC. | Cecilia Jones Chief Financial Officer | $134k 3,651 shares | -10% | |
| 57Moderate | AGIOS PHARMACEUTICALS, INC. | Theodore James Washburn Jr. Principal Accounting Officer | $315k 8,546 shares | -91% | |
| 0Weak | AGIOS PHARMACEUTICALS, INC. | David Scadden director | $8,000 200 shares | -1% | |
| 6Weak | AGIOS PHARMACEUTICALS, INC. | Brian Goff Chief Executive Officer | $406k 11,085 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.